What Your Worth
The Patient Already Know
I spent seventeen years inside this industry’s reporting lines. Four manufacturers, every seat from field sales to executive director. I know what the deck says on the way up, because I built some of those decks.
The board hears “same-store growth” and “injector productivity.” The injector hears “we’re restructuring commission this quarter.” The patient hears “that’s just swelling.”
Every layer is optimized to sell the layer above it a cleaner story than the one below it lived.
I used to think that was cynical. Now I understand it’s the operating system.
Once you see it, you can’t unsee it, and you start noticing the people closest to the revenue, the injectors, often understand their own economics the least. The system was designed that way. Each level the numbers become more opaque. It’s hard to know what you can’t see.
This issue, I’m pulling the math out into the open.
6.5x
How much one nurse multiplied their commission rate. Ten percent on gross to sixty-five on net.
If she could move it that much, what’s the rest of the room leaving on the table?
(Same practice. Same injector. Same patients.)
Every dollar in aesthetic medicine passes through four sets of hands. The patient pays it, the injector earns it, the owner books it, and the investor eventually values it. Each tier sees a different version of the same dollar, and none of them sees the full one.
Today’s patient is more informed than the industry has ever encountered. BCG and WWD call her the “optimizer.” Roughly fifteen million Americans spending around three thousand a year layering aesthetics, skincare, and longevity into one routine. Three in four of these “optimizers” research with AI first. The practitioner’s old monopoly on knowledge is gone. The patient now arrives confident and often outspoken. Whether she’s right or wrong, pretending otherwise is the fastest way to lose her.
Most injectors have no idea how their pay tracks the revenue they generate. They accept a structure handed to them at hire and stop questioning it once the math feels normal. Owners, meanwhile, often don’t know whether that structure is building loyalty or quietly leaking margin. This issue’s guide, Injector Commission Structures, lays out what each common structure rewards, so both sides walk in knowing the floor, the ceiling, and the incentive baked into the model.
Owners typically know their P&L cold. What’s tricky and can be elusive is their clinical exposure lurking beneath. A practice can have a healthy revenue number while accumulating risk an acquirer would quickly zero in on. The risk shows up in off-label patterns, documentation gaps, and comp structures nobody upstream has stress-tested. Owners run their own diligence in the quiet quarter before they sell. The ones who run it now, while there’s still time to fix it, walk into the deal with their valuation intact.
Bridgepoint agreed to pay up to $460M for Obagi this June, while Waldencast’s full market cap sat near $160M. Private buyers see what the public market doesn’t have access to, like detailed operating numbers and growth plans. What buyers can’t see is the reality on the ground: whether injectors had real training, whether that training moved outcomes, whether the production numbers come from a team about to walk.
Asymmetry collapses the moment any one of them starts asking. For an injector, that means knowing your numbers (cost-per-unit and net margin) before your next review. For an owner, running diligence on yourself before someone else runs it on you. For a manufacturer, knowing whether your training produced lasting ROI (for you and the practice) or just closed an order. For a PE-backed operator or investor, knowing what the injector knows.
No matter the tier, if you don’t know, ask. The work I do sits between those tiers, surfacing what each one isn’t seeing so the others can act on it. It’s how you close the gap before a competitor, a buyer, or your best injector closes it for you.
“Your floor sets your ceiling for every conversation you have.”
One more question before you go.
What’s one thing happening in aesthetics that leadership isn’t paying enough attention to?
I read every response.
